eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS REPORTS POSITIVE DATA UPDATES FROM
PHASE 2
EXPANSION COHORTS EVALUATING ZOTATIFIN IN PATIENTS WITH ER+
METASTATIC BREAST CANCER AT THE ASCO 2023 ANNUAL MEETING
* EFFECTOR THERAPEUTICS: PARTIAL RESPONSES IN 26% PATIENTS
TREATED
WITH ZOTATIFIN 0.07 MG/KG WITH FULVESTRANT & ABEMACICLIB IN
HEAVILY PRETREATED POPULATION
* EFFECTOR THERAPEUTICS INC: BOTH COMBINATIONS WERE
GENERALLY WELL
TOLERATED WITH LARGE MAJORITY OF ADVERSE EVENTS GRADE 1 OR 2
* EFFECTOR THERAPEUTICS INC: PARTIAL RESPONSE OBSERVED IN 1
OF 3
(33%) PATIENTS TREATED WITH ZOTATIFIN 0.1 MG/KG COMBINED WITH
FULVESTRANT (ZF DOUBLET)
* EFFECTOR THERAPEUTICS INC: REPORTING DATA FROM COMPLETED
DOSE
ESCALATION IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX9Mp7Nr
Further company coverage: EFTR.O